Jean-Francois Zagury

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Vaxconsulting, Neovacs, Peptinov Sas. Active years: 2002-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Francois Zagury. Retrieved from https://idiyas.com/inventor/jean-francois-zagury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 30.8

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1

Average Co-Inventor Count = 1.5

ph-index = 4

Forward Citations = 32(Granted Patents)

Company Filing History:

5. 1 out of 834,570

Other

patents

Years Active: 2002-2019

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10456456 - Anti-IL-6 vaccine composition (2019-10-29),

2. 9669077 - Method for treating chronic colitis and systemic sclerosis and for eliciting a protective immune reaction against human IL-6 (2017-06-06),

3. 8975399 - Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF (2015-03-10),

4. 8632781 - Immunogenic compounds comprising peptides of IL1β (2014-01-21),

5. 8529881 - Peptides for active anti-cytokine immunization (2013-09-10),

6. 8277792 - Peptides for active anti-cytokine immunization (2012-10-02),

7. 8147819 - Peptides for active anti-cytokine immunization (2012-04-03),

8. 7892558 - Isolated TNF-alpha peptide and pharmaceutical composition thereof (2011-02-22),

9. 7892529 - Peptides for active anti-cytokine immunization (2011-02-22),

10. 7641895 - Peptides for active anti-cytokine immunization (2010-01-05),

11. 7067246 - Method for determining prognosis of HIV infected individuals (2006-06-27),

12. 7022482 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2006-04-04),

13. 6420141 - Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids (2002-07-16),

Title: The Innovations of Jean-Francois Zagury

Introduction

Jean-Francois Zagury is a prominent inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of vaccine compositions. With a total of 13 patents to his name, Zagury's work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents is the Anti-IL-6 vaccine composition. This invention relates to a pharmaceutical composition that includes at least one polypeptide comprising a sequence of at least 8 contiguous amino acids, chosen from within the interleukin-6 sequence. Another notable patent is the method for treating chronic colitis and systemic sclerosis, which also involves a pharmaceutical composition with similar polypeptide sequences. These innovations highlight his focus on addressing critical health issues through advanced medical solutions.

Career Highlights

Throughout his career, Jean-Francois Zagury has worked with notable companies such as Vaxconsulting and Neovacs. His experience in these organizations has allowed him to refine his expertise in vaccine development and pharmaceutical research. His contributions have been instrumental in advancing the understanding and treatment of diseases related to interleukin-6.

Collaborations

Zagury has collaborated with several professionals in his field, including Daniel Zagury and Matthieu Montes. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jean-Francois Zagury's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a commitment to improving health outcomes through scientific advancements. His contributions are likely to have a lasting impact on medical research and treatment methodologies.

Profile summary based on public USPTO records.